The newly approved PCSK9 inhibitors are a major advance in cholesterol-lowering drug therapy. Gregory Curfman, MD and Editor in Chief of Harvard Health Publications, has said that this advanced therapy may just rewrite the script for treating patients with chronic high cholesterol. However, this same therapy promises to further raise the stakes in the ongoing match […]
"Biopharmaceutical manufacturers have been taking it on the chin lately as prices continue to skyrocket. The battery continues as candidates vying for their respective party’s nomination for the 2016 presidential campaign take their positions. As Chris Seper reported via Matthew Herper at Forbes, Hillary Clinton and Bernie Sanders both identified the biopharmaceutical industry as their […]
October 2, 2015 - Curant COO, Marc O'Connor and Curant HCV Program Director, Amy Hampton in Managed Healthcare Executive - The days of biopharmaceutical manufacturers and payers operating in isolation are over. Trapped in the firestorm of prior authorizations, high-deductible plans and ultra-high-cost medications are the patients who need all the help they can get […]
All healthcare stakeholders are aware the day is coming when pharma manufacturers will need to go at-risk in order to secure inclusion of their high-cost drugs in plan formularies. This shouldn’t be viewed as simply a unilateral opportunity to force price concessions from manufacturers. Rather, this is an opportunity to place patient outcomes squarely in […]
We’ve talked about who we are: Curant Health is a team of healthcare experts who provide individualized, patient-centered services proven to deliver improved health outcomes. We’ve talked about what we bring to the healthcare table, including the improved outcomes we’ve demonstrated in HIV treatment and diabetes. Now it’s time to talk about ways we enjoy […]
As the creation of new drugs for chronic illness progresses, we ask ourselves certain questions when thinking from a biopharmaceutical manufacturer point of view: What key points do biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for distribution networks? What capabilities do they prioritize most highly? What factors benefit patients the most? Three metrics come […]
September 16, 2015 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - In the current landscape of specialty drugs for chronic care, including PCSK9 inhibitors topping $1,000 per month for life, what are the key factors biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for their distribution networks? We are always interested in learning […]
September 9, 2015 - Curant President and CEO, Patrick Dunham, in Managed Healthcare Executive - In the midst of the shift from fee-for-service to value based healthcare, pharmaceutical manufacturers continue churning out high-priced therapies. They may be justified to do so as long as the outcomes of the medication therapies outweigh the costs. We define “value” as […]
There’s an 80/20 rule when it comes to healthcare – 80% of healthcare cost comes from 20% of the populace, the chronically ill. According to the Deloitte Center for Health Solutions, healthcare spend in the United States is expected to eclipse $4 trillion this year. Take an estimated population of 319 million into consideration; that […]
August 30, 2015 - Curant COO, Marc O'Connor, in MedCity News - If it seems like every industry has some sort of 80-20 rule, that’s because it does. Entrepreneurs will tell you 80 percent of their profits come from 20 percent of their customers. Customer service reps will tell you they spend 80 percent of their time […]
